Osteopore®

Q3 CY26 Quarterly Report

30 October 2026



ASX:OSX

Quarterly highlights

Osteopore Limited (ASX:OSX) ("**Osteopore**" or the "**Company**"), a revenue-generating manufacturer of regenerative implants that empower natural tissue regeneration, is pleased to release its quarterly results and Appendix 4C Quarterly Cash Flow Report for the three months ended 30 September 2026.



Osteopore captures record revenue of AUD 859k for Q3 CY26

Osteopore reports record quarterly revenue of AUD 859k (~SGD 776k) for Q3 CY26, representing a 27% QoQ and 6% YoY growth



OSX and Zimmer gain craniofacial market access to Saudi Arabia

Osteopore's market access to Saudi Arabia for its craniofacial products is in partnership with Zimmer Biomet (NYSE and SIX: ZBH).




OSX strikes deal for ortho devices in 5 countries in the Middle East

Osteopore announced an orthopaedic deal with Al-Umnia Medical LLC (Al-Umnia) across 5 countries in the Middle East

Quarterly highlights

Osteopore Limited (ASX:OSX) ("**Osteopore**" or the "**Company**"), a revenue-generating manufacturer of regenerative implants that empower natural tissue regeneration, is pleased to release its quarterly results and Appendix 4C Quarterly Cash Flow Report for the three months ended 30 September 2026.



Osteopore secures Thailand orthopaedic market access

Valued at USD 749 million in 2025, this market is projected to reach USD 1.5 billion by 2033 at a compound annual growth rate of 9.2%.



First custom orthopaedic implant delivered and implanted in Hainan, China

Osteopore's customised implant was used to reconstruct a 12cm bone defect in the upper limb of a patient.



OSX completes co-development project for neurosurgical guide

The team is now seeking additional resource to progress this to the clinical evaluation phase.

We are pleased to report a record quarter of revenue in Q3 2026, representing a 27% growth Quarter-on-Quarter, and a 6% growth Year-on-Year.


In this quarter, we have also secured market access to the craniofacial market in Saudi Arabia, as well as the orthopaedic market in Thailand. These market access approvals provide us with the impetus for commercial traction going forwards.

Our custom orthopaedic product has also been successfully implanted in our first patient in Hainan, China, shortly after our approval in May 2026.

We have also completed the co-development project for a precision guide used in neurosurgery, and look forward to the next stage of development with the National University Hospital Singapore.

Mark Leong
Executive Chairman

Osteopore reports record quarterly revenue of AUD 859K (~SGD 776K) for Q3 CY26, representing a 27% QoQ and 6% YoY growth



***A$/S$:** Average exchange rate of each quarter is obtained from https://www.rba.gov.au/





OSX strikes deal for orthopaedic devices in 5 countries in the Middle East [1]

- On 6 August 2026 [1], Osteopore announced an orthopaedic deal with Al-Umnia Medical LLC (Al-Umnia) across 5 countries in the Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Bahrain.
- Osteopore and Al-Umnia have commenced with product registration in the 5 countries, according to each country's requirements and practice.
- The GCC orthopaedic devices market was valued at approximately USD 897.5 million in 2025 and is forecast to reach USD 1.55 billion by 2034 (6.04% CAGR), with the UAE the largest single market at 31.5% share. Synthetic bone substitutes form a distinct segment within this market [2].

1 ASX announcement: 'OSX strikes orthopaedic deal for 5 Middle East countries', 6 August 2026

2 IMARC Group, GCC Orthopaedic Devices Market Report, 2026-2034





OSX and Zimmer gain craniofacial market access to Saudi Arabia [1]

- As previously announced on 16 July 2024 [2], Osteopore entered into an agreement with Zimmer Biomet to distribute Osteopore's craniofacial products in EMEA and APAC.
- Saudi Arabia is a country within the EMEA distribution partnership. It is the largest economy in the Middle East and the de facto leader of the Gulf Cooperation Council, with its population and advanced healthcare infrastructure under Vision 2030 widely regarded as the clinical and commercial benchmark for the broader GCC.
- Zimmer Biomet established a commercial presence in Saudi Arabia in 2018, building a team across clinical, sales, operations, and warehousing functions. The Company has since further deepened its regional commitment, opening a dedicated regional headquarters in Saudi Arabia focused on physician education and training [3].

1 ASX announcement: 'OSX & Zimmer gain craniofacial market access to Saudi Arabia', 7 July 2026
2 ASX announcement: 'Osteopore strikes Exclusive Distribution with Zimmer Biomet', 16 July 2024

3 https://pharmaboardroom.com/interviews/amr-kenawi-general-manager-zimmer-biomet-saudi-arabia/



Osteopore secures Thailand orthopaedic market access [1]

- Osteopore has secured market access in Thailand for the full range of its orthopaedic products.
- The Thai orthopaedic devices market was valued at USD 749 million in 2025 and projected to reach USD 1.5 billion by 2033 at a compound annual growth rate of 9.2% — among the fastest in the Asia-Pacific region [2].
- Osteopore has also secured its supply chain and logistics network into Thailand through a partnership with DCH Auriga (Auriga), an Asia-based integrated market management provider specialising in healthcare.

1 ASX announcement: 'OSX secures market access to Thailand orthopaedic market', 9 September 2026
2 Datacube Research, Thailand Orthopedic Devices Market, 2025.



OSX delivers and implants first Hainan orthopaedic device [1, 2]

- On 26 May 2026 [3], Osteopore received approval from the Hainan Medical Products Administration (Hainan FDA) for the clinical use of its orthopaedic custom medical devices at the Hainan branch hospital of the prestigious Shanghai Ruijin Hospital, located within the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
- Following the approval, Osteopore is pleased to report that it has delivered its first custom orthopaedic implant in Hainan and completed the first surgery [1, 2], where a 12cm bone defect in the upper limb of a patient was reconstructed following the resection of a malignant tumour.
- The China orthopaedic devices market was valued at USD 2.5 billion (AUD 3.5 billion) in 2024, and is projected to reach USD 4.5 billion (AUD 6.4 billion) by 2035, at a CAGR of 5.6% [4].

1 ASX announcement: 'First OSX custom orthopaedic implant delivered to Hainan', 14 July 2026.
2 ASX announcement: 'OSX completes first Hainan custom orthopaedic implant', 3 August 2026.

3 ASX announcement: 'OSX secures Hainan FDA approval for orthopaedic devices', 26 May 2026
4 https://www.marketresearchfuture.com/reports/china-orthopedic-devices-market-44863



OSX completes co-development project for neurosurgical guide [1]

- As announced on 10 March 2026 [2], Osteopore signed a collaboration agreement with the National University Hospital of Singapore (NUH) to develop a **novel ventricular catheter guide to enhance precision and patient safety in neurosurgery**.
- Osteopore is delighted to announce that it has successfully completed the project, which comprised two phases: the first focused on the design and prototyping of the external ventricular drain (EVD) guide, while the second involving simulated testing of the EVD guide in dry bone models.
- The project team is now seeking additional funding opportunity to progress this project into clinical evaluation phase.
- The **global market opportunity** for a mechanical intra-operative external ventricular drain (EVD) guide is substantial, with an **estimated 20,000 to 25,000 EVD procedures performed annually just in the United States** [3].

1 ASX announcement: 'OSX completes co-development project for neurosurgical guide', 2 July 2026
2 ASX announcement: 'OSX and NUH to co-develop surgical guide in neurosurgery', 10 March 2026
3 Data published by the US Department of Health and Human Services, Centers for Diseases Control and Prevention. "Morbidity and Mortality Weekly Report", 11 April 2024.

Appendix 4C - Quarterly cashflow report

Corporate and financial summary

The attached Appendix 4C provides details of the cashflows for the quarter ended 30 September 2026.

As at 30 September 2026, the Company has a cash balance of approximately A$712,000.

Net cash used in operating activities during the quarter amounted to approximately A$559,000, a decrease of approximately A$132,000 (19%) compared to the previous quarter (A$691,000). The improvement was mainly driven by higher receipts from customers, together with lower product manufacturing and operating costs and research and development payments. This was partially offset by higher administration and corporate costs during the quarter.

The Company maintains access to the redeemable convertible note facility with an aggregate nominal value of up to A$20,000,000, of which A$6,000,000 had been drawn as at 30 September 2026, leaving A$14,000,000 in available funding.

Related party transactions

Payments in the September quarter to related parties of approximately A$174,000 at Item 6 in Appendix 4C, comprised of director fees and salaries.

This presentation has been authorised and approved in accordance with the Company's published continuous disclosure policy and has been approved by the Board.

Osteopore®

Mark Leong
Executive Chairman
E: mark_leong@osteopore.com

Lim Yujing PhD
Chief Executive Officer & Chief Technology Officer
E: lim_yujing@osteopore.com



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Osteopore Limited	
ABN	**Quarter ended ("current quarter")**
65 630 538 957	30 September 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	678	1,877
1.2	Payments for		
	(a) research and development	(15)	(175)
	(b) product manufacturing and operating costs	(190)	(713)
	(c) marketing, business development & investor relations (including allocated staff costs)	(316)	(1,052)
	(d) leased assets	(28)	(86)
	(e) staff costs (other than allocated staff costs under note 1.2(c))	(399)	(1,153)
	(f) administration and corporate costs	(387)	(954)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1	4
1.5	Interest and other costs of finance paid	(5)	(6)
1.6	Income taxes paid	-	4
1.7	Government grants and tax incentives	102	234
1.8	Other (dossier fee)	-	565
1.9	**Net cash from / (used in) operating activities**	**(559)**	**(1,455)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(5)	(42)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	(4)	(49)
2.4	Dividends received (see note 3)	-	-
2.5	Other	-	-
2.6	**Net cash from / (used in) investing activities**	**(9)**	**(91)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	1,750
3.3	Proceeds from exercise of share options	-	1
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(105)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other	-	-
3.10	**Net cash from / (used in) financing activities**	-	**1,646**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,255	627

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(559)	(1,455)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(9)	(91)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	1,646
4.5	Effect of movement in exchange rates on cash held	25	(15)
4.6	**Cash and cash equivalents at end of period**	**712**	**712**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	706	1,249
5.2	Call deposits	6	6
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**712**	**1,255**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	174
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Payments made to Directors related to:

1. Non-executive director fees and superannuation;
2. Executive director fees and salaries

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	20,000	6,000
7.4	**Total financing facilities**	**20,000**	**6,000**
7.5	**Unused financing facilities available at quarter end**		**14,000**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

On 24 December 2024, the Company entered into a subscription agreement to issue 4% redeemable convertible notes with an aggregate nominal value of up to $20,000,000 comprising of 4 equal tranches of nominal value of $5,000,000 each. Each tranche comprises 20 equal sub-tranches of $250,000 each. The face value of the convertible notes when issued is $50,000 each.

The interest amount is equivalent to 100% of the nominal value of the convertible notes at the rate of 4.0% per annum. The interest is payable in cash quarterly in arrears.

The maturity date of the notes is 36 months from the closing date of the first tranche. A Noteholder may at any time up to 7 calendar days prior to the maturity date exercise its right to convert all outstanding notes into shares. The convertible notes which are not redeemed or purchased, converted or cancelled by the Company on or before the maturity date shall be converted by the Company on the maturity date.

The conversion price shall be 80% of the average of the closing price per share on any 5 consecutive business days as selected by the noteholder during the 45 business days immediately preceding the relevant Conversion Date on which shares were traded on the ASX.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	(559)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	712
8.3	Unused finance facilities available at quarter end (Item 7.5)	14,000
8.4	Total available funding (Item 8.2 + Item 8.3)	14,712
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	**26.32**

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: NA

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: NA

3.	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer: NA	

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 October 2026

Authorised by: By the Board

.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g., Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.